Chronic Chagas Disease with cardiac involvement
Conditions
Interventions
The 60 patients included on this study will be evalluated on a specialized clinic for Chagas disease and will undergo laboratory tests, chest X-ray , ECG , stress test, cardiac magnetic resonance imag
Biological/vaccine
Sponsors
Hospital São Rafael
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Chagas disease confirmed by 2 different serological tests; optimized drug therapy; NYHA functional class II-III-IV or patients with the indeterminate form; patients of any gender and aged 18 to 70 years.
Exclusion criteria
Exclusion criteria: Valvulopathy with hemodynamic consequences; chronic use of immunosuppressive agents; renal failure on current treatment by dialysis; acute infections or systemic infections in accordance with the definition of sepsis ACCP/SCCM (American College of Chest Phisicians/Society of Critical Care Medicine); abuse alcohol or illicit drugs (Based on DSM IV), any comorbidity with impact on survival in two years; liver, pulmonary, hematologic, neoplastic, bone, inflammatory or infectious diseases.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome: Higher serum levels of galectin-3 in the patients with myocardium fibrosis; detected by ELISA; observing an increase of about 5 ng/mL in patients with myocardium fibrosis when compared with patients without fibrosis. | — |
Primary
| Measure | Time frame |
|---|---|
| Expected outcome: Higher serum levels of galectin-3 in the most severe forms of presentation of Chagas disease; detected by ELISA; observing an increase of about 5 ng/mL in patients with the most severe forms when compared with patients with the indeterminate form. | — |
Countries
Brazil
Contacts
Public ContactMilena Soares.
Centro de Biotecnologia e Terapia Celular
Outcome results
None listed